AR080023A1 - Formulacion de complejos que comprende aspirina revestida con una barrera que contiene aditivo hidrofobo e inhibidor de la hmg-coa reductasa - Google Patents
Formulacion de complejos que comprende aspirina revestida con una barrera que contiene aditivo hidrofobo e inhibidor de la hmg-coa reductasaInfo
- Publication number
- AR080023A1 AR080023A1 ARP110100246A ARP110100246A AR080023A1 AR 080023 A1 AR080023 A1 AR 080023A1 AR P110100246 A ARP110100246 A AR P110100246A AR P110100246 A ARP110100246 A AR P110100246A AR 080023 A1 AR080023 A1 AR 080023A1
- Authority
- AR
- Argentina
- Prior art keywords
- formulation
- hmg
- coa reductase
- complexes
- acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Botany (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se provee una formulacion de complejos para la prevencion o el tratamiento de enfermedades cardiovasculares, que comprende: a) aspirina revestida con una barrera que contiene un aditivo hidrofobo; y b) un inhibidor de la HMG-CoA reductasa, que tiene estabilidad de almacenamiento mejorada al prevenir el deterioro en la estabilidad de la HMG-CoA reductasa causado por el ácido salicílico, por ende siendo usada en el tratamiento de hipertension e hipercolesterolemia. Reivindicacion 3: La formulacion de complejos de acuerdo con la reivindicacion 1, caracterizada porque el aditivo hidrofobo se selecciona entre el grupo formado por: cera carnauba, monoestearato de glicerilo, monooleato de glicerilo, cera de abejas, etil celulosa, copolímero RS de aminoalquil metacrilato, copolímero de etil acrilato y metil metacrilato, cloruro de polivinilo, acetato de polivinilo, acetato de celulosa, y combinaciones de los mismos. Reivindicacion 4: La formulacion de complejos de acuerdo con la reivindicacion 1, caracterizada porque el inhibidor de la HMG-CoA reductasa se selecciona entre el grupo formado por: mevastatina, rosuvastatina, atorvastatina, lovastatina, pravastatina, pravastatina lactona, pitavastatina, bervastatina ,velostatina, simvastatina, rivastatina, fluvastatina, cerivastatina, e isomeros, sales y combinaciones de los mismos .- Reivindicacion 5: La formulacion de complejos de acuerdo con la reivindicacion 1, caracterizada porque la cantidad del inhibidor de la HMG-CoA reductasa oscila entre 5 y 80 mg. Reivindicacion 6: La formulacion de complejos de acuerdo con la reivindicacion 1, caracterizada porque la cantidad de aspirina oscila entre 10 mg y 2g. Reivindicacion 7: formulacion de complejos de acuerdo con la reivindicacion 1, caracterizada porque comprende, además, un agente estabilizador para mejorar la estabilidad del inhibidor de la HMG-CoA reductasa. Reivindicacion 9: La formulacion de complejos de acuerdo con la reivindicacion 8, caracterizada porque el antioxidante es tocoferol, hidroxitolueno butilado (BHT), hidroxianisol butilado (BHA), ácido ascorbico o ácido eritorbico, el mineral es CaCO3, MgCO3, NaHCO3, KH2PO4 o K2HPO3, el aditivo básico es meglumina, arginina o glicina, y el ácido orgánico es ácido cítrico o ácido fumárico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100009636A KR101193493B1 (ko) | 2010-02-02 | 2010-02-02 | 소수성 첨가제가 함유된 분리막으로 코팅된 아스피린 및 HMG?CoA 환원효소 억제제를 포함하는 복합제제 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR080023A1 true AR080023A1 (es) | 2012-03-07 |
Family
ID=44355918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110100246A AR080023A1 (es) | 2010-02-02 | 2011-01-26 | Formulacion de complejos que comprende aspirina revestida con una barrera que contiene aditivo hidrofobo e inhibidor de la hmg-coa reductasa |
Country Status (8)
Country | Link |
---|---|
US (1) | US20120301549A1 (es) |
EP (1) | EP2531199A4 (es) |
JP (1) | JP2013518873A (es) |
KR (1) | KR101193493B1 (es) |
CN (1) | CN102740857A (es) |
AR (1) | AR080023A1 (es) |
TW (1) | TW201141487A (es) |
WO (1) | WO2011096665A2 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR201005325A2 (tr) * | 2010-06-30 | 2012-01-23 | Bi̇lgi̇ç Mahmut | Atorvastatin ve aspirin içeren farmasötik formülasyonlar |
KR102240429B1 (ko) * | 2013-05-06 | 2021-04-15 | 한미약품 주식회사 | 로수바스타틴 또는 이의 약학적으로 허용되는 염이 함유된 필름 코팅층을 포함하는 복합 제형 |
EP2810644A1 (en) * | 2013-06-06 | 2014-12-10 | Ferrer Internacional, S.A. | Oral formulation for the treatment of cardiovascular diseases |
MX2019009213A (es) * | 2017-01-23 | 2019-09-27 | Dong Wha Pharm Co Ltd | Formulación compleja que comprende inhibidor de la hmg-coa reductasa y clopidogrel. |
WO2023204397A1 (ko) * | 2022-04-19 | 2023-10-26 | 한미약품 주식회사 | 아세틸살리실산 및 프로톤 펌프 저해제를 포함하는 약학적 조성물 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6235311B1 (en) * | 1998-03-18 | 2001-05-22 | Bristol-Myers Squibb Company | Pharmaceutical composition containing a combination of a statin and aspirin and method |
US6569461B1 (en) * | 1999-03-08 | 2003-05-27 | Merck & Co., Inc. | Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors |
KR100646576B1 (ko) * | 2005-02-15 | 2006-11-23 | 한국유나이티드제약 주식회사 | 고지혈증 환자의 동맥경화증 예방을 위한 에이치엠지이-씨오에이 환원효소 저해제 및 장용코팅된 아스피린을 함유하는 복합 펠렛 |
US20120015032A1 (en) * | 2007-08-13 | 2012-01-19 | Hanall Pharmaceutical Company, Ltd. | Combination preparation comprising inhibitor of hmg-coa reductase and aspirin and method for manufacturing the same |
KR20090030452A (ko) * | 2007-09-20 | 2009-03-25 | 한미약품 주식회사 | HMG-CoA 환원효소 억제제와 아스피린을 함유하는복합제제 |
GB2462022B (en) * | 2008-06-16 | 2011-05-25 | Biovascular Inc | Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof |
-
2010
- 2010-02-02 KR KR1020100009636A patent/KR101193493B1/ko not_active IP Right Cessation
-
2011
- 2011-01-26 WO PCT/KR2011/000541 patent/WO2011096665A2/en active Application Filing
- 2011-01-26 EP EP11739961.8A patent/EP2531199A4/en not_active Withdrawn
- 2011-01-26 US US13/576,585 patent/US20120301549A1/en not_active Abandoned
- 2011-01-26 AR ARP110100246A patent/AR080023A1/es unknown
- 2011-01-26 JP JP2012551908A patent/JP2013518873A/ja active Pending
- 2011-01-26 CN CN2011800078123A patent/CN102740857A/zh active Pending
- 2011-02-01 TW TW100103931A patent/TW201141487A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CN102740857A (zh) | 2012-10-17 |
KR101193493B1 (ko) | 2012-10-22 |
US20120301549A1 (en) | 2012-11-29 |
WO2011096665A2 (en) | 2011-08-11 |
WO2011096665A3 (en) | 2012-01-05 |
KR20110090060A (ko) | 2011-08-10 |
TW201141487A (en) | 2011-12-01 |
EP2531199A2 (en) | 2012-12-12 |
EP2531199A4 (en) | 2013-07-10 |
JP2013518873A (ja) | 2013-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR081032A1 (es) | Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan | |
RU2022100434A (ru) | Фармацевтические композиции, содержащие epa и сердечно-сосудистое средство, и способы их применения | |
AR080023A1 (es) | Formulacion de complejos que comprende aspirina revestida con una barrera que contiene aditivo hidrofobo e inhibidor de la hmg-coa reductasa | |
JP2008522970A5 (es) | ||
AR082930A1 (es) | Composiciones que comprenden una mezcla oleosa de acidos grasos, un tensioactivo y una estatina | |
AR095182A1 (es) | Composiciones de estatinas y ácidos grasos omega-3 | |
RU2012116079A (ru) | Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина и способы ее применения | |
JP2010047616A5 (es) | ||
RU2006102981A (ru) | Лекарственные формы, обеспечивающие контролируемое высвобождение ингибиторов белка-переносчика эфиров холестерина и немедленное высвобождение ингибиторов hmg-соа-редуктазы | |
RU2018120599A (ru) | Лечение смешанной дислипидемии | |
JP2007530528A5 (es) | ||
AR076835A1 (es) | Composiciones de comprimidos de desintegracion oral que comprenden combinaciones de drogas en dosis elevadas y reducidas. metodo. | |
AR051950A1 (es) | Comprimido multicapa con capas que se separan | |
UA106457C2 (ru) | Пероральная комплексная композиция, содержащая сложные эфиры жирной кислоты омега-3 и ингибитор hmg-coa редуктазы | |
JP2016517883A5 (es) | ||
MX2009003920A (es) | Estatina y acidos grasos omega 3 para reducir los niveles de apo b. | |
UY25159A1 (es) | Composiciones farmacéuticas conteniendo amlodipino y una estatina | |
CO6311069A2 (es) | Cápsulas que comprenden ácido acetilsalicílico, un inhibidor de la hmg-coa reductasa y un ace inhibidor para la prevención de enfermedades cardiovasculares | |
AR101724A1 (es) | COMPOSICIÓN FARMACÉUTICA Y COMBINACIÓN TERAPÉUTICA QUE COMPRENDE UN INHIBIDOR DE LA PROTEÍNA DE TRANSFERENCIA DEL ÉSTER COLESTERILO E INHIBIDORES DE LA HMG CoA REDUCTASA | |
WO2009059717A3 (en) | Pharmaceutical compositions containing statins and omega-3 fatty acids derivatives and their solid formulations for oral use | |
CL2015003561A1 (es) | Composición farmacéutica para administración por vía oral para su uso para la prevención y/o el tratamiento de una enfermedad cardiovascular. | |
JP2016515563A5 (es) | ||
AR088876A1 (es) | FORMULACION COMPLEJA ORAL QUE COMPRENDE ACIDO GRASO OMEGA-3 Y UN INHIBIDOR DE LA HMG-CoA REDUCTASA CON ESTABILIDAD MEJORADA | |
AR048668A1 (es) | Composiciones hipocolesterolemiantes y procedimiento para prepararlas | |
WO2014107657A3 (en) | Cholesterol-lowering compounds in synergistic combination with lipid metabolism-altering compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |